Catalent Inc (NYSE:CTLT) – Equities researchers at First Analysis issued their Q2 2019 earnings estimates for shares of Catalent in a report issued on Wednesday. First Analysis analyst anticipates that the company will post earnings per share of $0.48 for the quarter. First Analysis has a “Equal Weight” rating on the stock.
Other equities analysts also recently issued reports about the company. Royal Bank of Canada set a $48.00 price target on Catalent and gave the company a “buy” rating in a report on Monday. Stephens downgraded Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target for the company in a report on Monday, November 6th. Finally, BidaskClub downgraded Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $45.60.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The firm’s quarterly revenue was up 25.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.27 earnings per share.
Several institutional investors have recently added to or reduced their stakes in CTLT. American Century Companies Inc. boosted its position in Catalent by 755.3% in the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after purchasing an additional 2,323,971 shares during the last quarter. Eagle Asset Management Inc. boosted its position in Catalent by 290.9% in the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after purchasing an additional 858,600 shares during the last quarter. Emerald Advisers Inc. PA boosted its position in Catalent by 1,072.2% in the third quarter. Emerald Advisers Inc. PA now owns 604,207 shares of the company’s stock worth $24,120,000 after purchasing an additional 552,663 shares during the last quarter. Emerald Mutual Fund Advisers Trust purchased a new position in Catalent in the third quarter worth about $18,420,000. Finally, State Street Corp boosted its position in Catalent by 10.7% in the second quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after purchasing an additional 418,196 shares during the last quarter. 98.86% of the stock is currently owned by institutional investors.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.